Fly News Breaks for July 30, 2019
Jul 30, 2019 | 07:39 EDT
Credit Suisse analyst Evan Seigerman raised his price target for Neurocrine to $110 from $95 and raised Ingrezza sales to $200M in Q3 following the "solid" quarterly beat. The analyst believes that Ingrezza has much more room to grow, and that the company's expanded promotional efforts are likely to drive continued penetration into the addressable TD market which he estimates to be over 500k patients in the U.S. Seigerman reiterates an Outperform rating on the shares.
News For NBIX From the Last 2 Days
There are no results for your query NBIX